134 related articles for article (PubMed ID: 38488679)
1. The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.
Lee HW; Kim KH; Ahn SH; Lee HC; Choi J
Liver Int; 2024 Jun; 44(6):1448-1455. PubMed ID: 38488679
[TBL] [Abstract][Full Text] [Related]
2. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
Kobayashi T; Iwaki M; Nogami A; Kawamura N; Honda Y; Ogawa Y; Imajo K; Yoneda M; Saito S; Nakajima A
J Gastroenterol; 2024 Jan; 59(1):56-65. PubMed ID: 37845417
[TBL] [Abstract][Full Text] [Related]
3. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
Lin H; Lee HW; Yip TC; Tsochatzis E; Petta S; Bugianesi E; Yoneda M; Zheng MH; Hagström H; Boursier J; Calleja JL; Goh GB; Chan WK; Gallego-Durán R; Sanyal AJ; de Lédinghen V; Newsome PN; Fan JG; Castéra L; Lai M; Harrison SA; Fournier-Poizat C; Wong GL; Pennisi G; Armandi A; Nakajima A; Liu WY; Shang Y; de Saint-Loup M; Llop E; Teh KK; Lara-Romero C; Asgharpour A; Mahgoub S; Chan MS; Canivet CM; Romero-Gomez M; Kim SU; Wong VW;
JAMA; 2024 Apr; 331(15):1287-1297. PubMed ID: 38512249
[TBL] [Abstract][Full Text] [Related]
4. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
[TBL] [Abstract][Full Text] [Related]
5. Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis.
Wang JH; Chuah SK; Lu SN; Hung CH; Kuo CM; Tai WC; Chiou SS
Liver Int; 2014 Oct; 34(9):1340-8. PubMed ID: 24620731
[TBL] [Abstract][Full Text] [Related]
6. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography.
Masuzaki R; Tateishi R; Yoshida H; Goto E; Sato T; Ohki T; Imamura J; Goto T; Kanai F; Kato N; Ikeda H; Shiina S; Kawabe T; Omata M
Hepatology; 2009 Jun; 49(6):1954-61. PubMed ID: 19434742
[TBL] [Abstract][Full Text] [Related]
7. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
[TBL] [Abstract][Full Text] [Related]
8. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
9. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
[TBL] [Abstract][Full Text] [Related]
10. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.
John BV; Dang Y; Kaplan DE; Jou JH; Taddei TH; Spector SA; Martin P; Bastaich DR; Chao HH; Dahman B
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):778-788.e7. PubMed ID: 38061410
[TBL] [Abstract][Full Text] [Related]
11. Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case-control study.
Nahon P; Kettaneh A; Lemoine M; Seror O; Barget N; Trinchet JC; Beaugrand M; Ganne-Carrié N
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):214-9. PubMed ID: 19212210
[TBL] [Abstract][Full Text] [Related]
12. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
[TBL] [Abstract][Full Text] [Related]
13. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
14. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
Nakai M; Yamamoto Y; Baba M; Suda G; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Sho T; Morikawa K; Ogawa K; Furuya K; Sakamoto N
Sci Rep; 2022 Jan; 12(1):1449. PubMed ID: 35087141
[TBL] [Abstract][Full Text] [Related]
15. The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD.
Chouik Y; Aubin A; Maynard-Muet M; Segrestin B; Milot L; Hervieu V; Zoulim F; Disse E; Levrero M; Caussy C
Obesity (Silver Spring); 2024 Jun; 32(6):1114-1124. PubMed ID: 38699960
[TBL] [Abstract][Full Text] [Related]
16. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).
Jung KS; Kim SU; Ahn SH; Park YN; Kim DY; Park JY; Chon CY; Choi EH; Han KH
Hepatology; 2011 Mar; 53(3):885-94. PubMed ID: 21319193
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
[TBL] [Abstract][Full Text] [Related]
18. Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis.
Fan R; Yu N; Li G; Arshad T; Liu WY; Wong GL; Liang X; Chen Y; Jin XZ; Leung HH; Chen J; Wang XD; Yip TC; Sanyal AJ; Sun J; Wong VW; Zheng MH; Hou J
Liver Int; 2024 Mar; 44(3):749-759. PubMed ID: 38131420
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
Gidener T; Yin M; Dierkhising RA; Allen AM; Ehman RL; Venkatesh SK
Hepatology; 2022 Feb; 75(2):379-390. PubMed ID: 34510513
[TBL] [Abstract][Full Text] [Related]
20. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
